Cyclic GMP-Dependent Protein Kinase Type I

A cyclic GMP-dependent protein kinase subtype that is expressed in SMOOTH MUSCLE tissues and plays a role in regulation of smooth muscle contraction. Two isoforms, PKGIalpha and PKGIbeta, of the type I protein kinase exist due to alternative splicing of its mRNA.

Also Known As:

PKGI beta; PKGIalpha; PKGIbeta; Protein Kinase G I alpha; cGK-Ialpha; cGMP-Dependent Protein Kinase I; cGMP-Dependent Protein Kinase Ialpha; cGMP-Dependent Protein Kinase Ibeta; Cyclic GMP Dependent Protein Kinase Type I; cGMP Dependent Protein Kinase I; cGMP Dependent Protein Kinase Ialpha; cGMP Dependent Protein Kinase Ibeta

Networked: 35 relevant articles (1 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Hofmann, Franz: 7 articles (10/2015 - 03/2004)
2.	Feil, Robert: 4 articles (12/2019 - 03/2004)
3.	Lukowski, Robert: 4 articles (09/2014 - 03/2010)
4.	Domes, Katrin: 3 articles (10/2015 - 08/2013)
5.	Rybalkin, Sergei D: 3 articles (09/2014 - 03/2010)
6.	Niederberger, Ellen: 3 articles (12/2009 - 02/2008)
7.	Geisslinger, Gerd: 3 articles (08/2008 - 03/2004)
8.	Ruth, Peter: 3 articles (08/2008 - 03/2004)
9.	Schmidtko, Achim: 3 articles (08/2008 - 03/2004)
10.	Tegeder, Irmgard: 3 articles (08/2008 - 03/2004)

Related Diseases

1.	Reperfusion Injury 12/15/2006 - "PKGIalpha is present in the heart, although its role in protection against ischemia/reperfusion injury is not known. "
2.	Necrosis 12/15/2006 - "The necrosis observed in 33.7 +/- 1.6% of total myocytes in the SI-RO control group was reduced to 18.6 +/- 0.8% by PKGIalpha (mean +/- S.E., n = 7, p < 0.001). " 12/15/2006 - "We investigated the direct effect of PKGIalpha against necrosis and apoptosis following simulated ischemia (SI) and reoxygenation (RO) in cardiomyocytes. " 12/15/2006 - "A scavenger of reactive oxygen species, as well as inhibitors of phosphatidylinositol 3-kinase, ERK, JNK1, and NOS, also blocked PKGIalpha-mediated protection against necrosis and apoptosis. " 12/15/2006 - "5-Hydroxydecanoate and glibenclamide abolished PKGIalpha-mediated protection against necrosis and apoptosis. "
3.	Fibrosis (Cirrhosis) 05/01/2014 - "Our previous studies support the protective effect of cGMP and cGMP-dependent protein kinase I (PKG-I) pathway on the development of renal fibrosis. " 08/01/2014 - "Gene-targeting studies have not defined a clear role for its major downstream effector, cGMP-dependent protein kinase I (cGKI), in cardiac hypertrophy, but do implicate cGMP-cGKI signaling in fibrosis and I/R injury. " 09/02/2014 - "Conflicting results have been reported for the roles of cGMP and cGMP-dependent protein kinase I (cGKI) in various pathological conditions leading to cardiac hypertrophy and fibrosis. " 09/02/2014 - "Roles of cGMP-dependent protein kinase I (cGKI) and PDE5 in the regulation of Ang II-induced cardiac hypertrophy and fibrosis." 09/01/2014 - "In response to 21 days of transverse aortic constriction, mice with cardiomyocyte-restricted inactivation (knockout) of the ANP receptor (guanylyl cyclase [GC]-A) or the downstream cGMP-dependent protein kinase I developed enhanced left ventricular hypertrophy and fibrosis together with contractile dysfunction. "
4.	Cardiomegaly (Heart Hypertrophy) 10/01/2015 - "Signaling via cGMP-dependent protein kinase I (cGKI) and canonical transient receptor potential (TRPC) channels appears to be involved in the regulation of cardiac hypertrophy. " 03/23/2010 - "Cardiac hypertrophy is not amplified by deletion of cGMP-dependent protein kinase I in cardiomyocytes." 08/01/2014 - "Gene-targeting studies have not defined a clear role for its major downstream effector, cGMP-dependent protein kinase I (cGKI), in cardiac hypertrophy, but do implicate cGMP-cGKI signaling in fibrosis and I/R injury. " 09/02/2014 - "Conflicting results have been reported for the roles of cGMP and cGMP-dependent protein kinase I (cGKI) in various pathological conditions leading to cardiac hypertrophy and fibrosis. " 09/02/2014 - "Roles of cGMP-dependent protein kinase I (cGKI) and PDE5 in the regulation of Ang II-induced cardiac hypertrophy and fibrosis."
5.	Hyperalgesia 01/01/2021 - "Previous studies have implicated peripherally localized cGMP-dependent protein kinase I (PKG-I) in plasticity of nociceptors and spinal synaptic transmission as well as inflammatory hyperalgesia. " 03/02/2004 - "Reduced inflammatory hyperalgesia with preservation of acute thermal nociception in mice lacking cGMP-dependent protein kinase I." 12/25/2009 - "There is convincing evidence that nitric oxide (NO), cGMP and cGMP-dependent protein kinase I (PKG-I) are involved in the development of hyperalgesia in response to noxious stimuli. " 03/31/2000 - "These results suggest that the activation of cGMP-dependent protein kinase Ialpha is required for NMDA- or NO-produced facilitation of thermal hyperalgesia at the spinal cord level." 03/31/2000 - "Activation of cGMP-dependent protein kinase Ialpha is required for N-methyl-D-aspartate- or nitric oxide-produced spinal thermal hyperalgesia."

Related Drugs and Biologics

1.	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)
2.	Reactive Oxygen Species (Oxygen Radicals)
3.	Glyburide (Glibenclamide)
4.	5-hydroxydecanoic acid
5.	N-Methyl-D-Aspartate Receptors (NMDA Receptors)
6.	Nitric Oxide (Nitrogen Monoxide)
7.	Cyclic GMP-Dependent Protein Kinase Type I
8.	Guanylate Cyclase (Guanylyl Cyclase)
9.	Cell-Penetrating Peptides
10.	Nitric Oxide Synthase Type I (Neuronal Nitric Oxide Synthase)

Related Therapies and Procedures

1.	Therapeutics